LONDON, September 25, 2018 /PRNewswire/ --
Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib
The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022. In 2017, the chemotherapy segment held 69% of the global acute myeloid leukaemia market.
(Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 135-page report you will receive 92 charts- all unavailable elsewhere.
The 135-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
Global Acute Myeloid Leukaemia Market from 2018-2028
Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type: Chemotherapy: Cytarabine, Daunorubicin, Others Targeted Therapy: Midostaurin, Enasidenib, Others
This report provides individual revenue forecasts to 2028 for these regional and national markets: North America: US, Canada, and Mexico Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA
Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market: Bristol-Myers Squibb Company Celgene Clavis Pharma ASA Daiichi Sankyo Eisai GSK Novartis Roche Sunesis Pharmaceuticals Teva
This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.
This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.
Visiongain's study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.
Buy our report today Global Acute Myeloid Leukaemia Market Forecast 2018-2028: Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.
To request a report overview of this report please contact Sara Peerun at [email protected]or refer to our website: https://www.visiongain.com/report/global-acute-myeloid-leukaemia-market-forecast-2018-2028/
AbbVie Agios Pharmaceuticals, Inc. Ambit Biosciences Corporation Amgen Animas Corporation Astex B. Braun Melsungen AG Baxter, Becton, Dickinson and Company (BD) Bayer Boehringer Ingelheim Bristol-Myers Squibb Company (Bristol-Myers) Celator Pharmaceuticals, Inc. Celgene Clavis Pharma ASA (Clavis Pharma) Cyclacel Daiichi Pharmaceutical Daiichi Sankyo Eisai Co., Ltd. (Eisai) F. Hoffmann-La Roche Ltd. (Roche) Fresenius SE & Co. KGaA GlaxoSmithKline plc (GSK) GLOBOCAN Hospira Medtronic Moog Inc. NeoMed Norsk Hydro Novartis Onyx Pharmaceuticals Sankyo Seattle Genetics Smiths Group Plc., Sunesis Pharmaceuticals, Inc. (Sunesis) TEVA Pharmaceutical Industries Limited (TEVA) List of Organizations Mentioned in the Report American Cancer Organization Baylor Scott and White Research Institute Benaroya Research Institute at Virginia Mason Beth Israel Deaconess Medical Center Breslin Cancer Center Center for Blood Disorders and Stem Cell Transplantation Charles A. Sammons Cancer Center Columbia University Medical Dana Farber Cancer Institute Duke Cancer Center European Commission Fred Hutchinson Cancer Research Center Health Canada Herbert Irving Comprehensive Cancer Center Institute of Hematology & Blood Diseases Hospital,Tianjin James Graham Brown Cancer Center Legacy Emanuel Hospital & Health Center Mary Babb Randolph Cancer Center Massachusetts general Hospital Mayo Clinic MD Anderson Cancer Center Medical College of Wisconsin Cancer Center Medizinische Klinik und Poliklinik I Memorial Sloan Kettering Cancer Center Michigan State University Nantes University Hospital National Cancer Institute New Jersey Hematology Oncology Associates Northwestern University Ochsner Medical Center Penn State Hershey Cancer Institute-Clinical Trials Office Perelman Center for Advanced Medicine Princess Margaret Hospital St. Francis Cancer Center St. Joseph Mercy Hospital St. Vincent's Comprehensive Cancer Center Swedish Cancer Institute The Gayle and Tom Benson Cancer Center The University of Hong Kong The University of Iowa The University of Texas MD Anderson Cancer Center Thomas Jefferson University U.S. Food and Drug Administration (FDA) UCLA Medical Center, Division of Hematology/Oncology University Hospital, Caen University of Kansas Cancer Center University of Kansas Medical Center Research Institute University of Kentucky University of Louisville University of Michigan Health System University of Pennsylvania University of Texas M.D. Anderson Cancer Center VA Caribbean Healthcare System Weill Cornell Medical College Weill Medical College of Cornell University West Virginia University World Health Organization (WHO)
To see a report overview please e-mail Sara Peerun on [email protected]
SOURCE Visiongain
Advertisement
Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib
The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022. In 2017, the chemotherapy segment held 69% of the global acute myeloid leukaemia market.
Advertisement
(Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 135-page report you will receive 92 charts- all unavailable elsewhere.
The 135-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
Global Acute Myeloid Leukaemia Market from 2018-2028
Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type: Chemotherapy: Cytarabine, Daunorubicin, Others Targeted Therapy: Midostaurin, Enasidenib, Others
This report provides individual revenue forecasts to 2028 for these regional and national markets: North America: US, Canada, and Mexico Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA
Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market: Bristol-Myers Squibb Company Celgene Clavis Pharma ASA Daiichi Sankyo Eisai GSK Novartis Roche Sunesis Pharmaceuticals Teva
This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.
This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.
Visiongain's study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.
Buy our report today Global Acute Myeloid Leukaemia Market Forecast 2018-2028: Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.
To request a report overview of this report please contact Sara Peerun at [email protected]or refer to our website: https://www.visiongain.com/report/global-acute-myeloid-leukaemia-market-forecast-2018-2028/
AbbVie Agios Pharmaceuticals, Inc. Ambit Biosciences Corporation Amgen Animas Corporation Astex B. Braun Melsungen AG Baxter, Becton, Dickinson and Company (BD) Bayer Boehringer Ingelheim Bristol-Myers Squibb Company (Bristol-Myers) Celator Pharmaceuticals, Inc. Celgene Clavis Pharma ASA (Clavis Pharma) Cyclacel Daiichi Pharmaceutical Daiichi Sankyo Eisai Co., Ltd. (Eisai) F. Hoffmann-La Roche Ltd. (Roche) Fresenius SE & Co. KGaA GlaxoSmithKline plc (GSK) GLOBOCAN Hospira Medtronic Moog Inc. NeoMed Norsk Hydro Novartis Onyx Pharmaceuticals Sankyo Seattle Genetics Smiths Group Plc., Sunesis Pharmaceuticals, Inc. (Sunesis) TEVA Pharmaceutical Industries Limited (TEVA) List of Organizations Mentioned in the Report American Cancer Organization Baylor Scott and White Research Institute Benaroya Research Institute at Virginia Mason Beth Israel Deaconess Medical Center Breslin Cancer Center Center for Blood Disorders and Stem Cell Transplantation Charles A. Sammons Cancer Center Columbia University Medical Dana Farber Cancer Institute Duke Cancer Center European Commission Fred Hutchinson Cancer Research Center Health Canada Herbert Irving Comprehensive Cancer Center Institute of Hematology & Blood Diseases Hospital,Tianjin James Graham Brown Cancer Center Legacy Emanuel Hospital & Health Center Mary Babb Randolph Cancer Center Massachusetts general Hospital Mayo Clinic MD Anderson Cancer Center Medical College of Wisconsin Cancer Center Medizinische Klinik und Poliklinik I Memorial Sloan Kettering Cancer Center Michigan State University Nantes University Hospital National Cancer Institute New Jersey Hematology Oncology Associates Northwestern University Ochsner Medical Center Penn State Hershey Cancer Institute-Clinical Trials Office Perelman Center for Advanced Medicine Princess Margaret Hospital St. Francis Cancer Center St. Joseph Mercy Hospital St. Vincent's Comprehensive Cancer Center Swedish Cancer Institute The Gayle and Tom Benson Cancer Center The University of Hong Kong The University of Iowa The University of Texas MD Anderson Cancer Center Thomas Jefferson University U.S. Food and Drug Administration (FDA) UCLA Medical Center, Division of Hematology/Oncology University Hospital, Caen University of Kansas Cancer Center University of Kansas Medical Center Research Institute University of Kentucky University of Louisville University of Michigan Health System University of Pennsylvania University of Texas M.D. Anderson Cancer Center VA Caribbean Healthcare System Weill Cornell Medical College Weill Medical College of Cornell University West Virginia University World Health Organization (WHO)
To see a report overview please e-mail Sara Peerun on [email protected]
SOURCE Visiongain
